P-089 - FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial. - Fernández Montes, A.; Martinez Lago, N.; De la Cámara Gómez, J.; Covela Rúa, M.; Cousillas Castiñeiras, A.; Gonzalez Villarroel, P.; Méndez Méndez, J. (Annals of Oncology, 2019)